Luis J Fernandez
Overview
Explore the profile of Luis J Fernandez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
291
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stojkovic Buric S, Podolski-Renic A, Dinic J, Stankovic T, Jovanovic M, Hadzic S, et al.
Oxid Med Cell Longev
. 2019 Apr;
2019:3061607.
PMID: 30984333
The main reasons for the inefficiency of standard glioblastoma (GBM) therapy are the occurrence of chemoresistance and the invasion of GBM cells into surrounding brain tissues. New therapeutic approaches obstructing...
2.
Gonzalez I, Earl J, Fernandez L, Sainz B, Pinto A, Monge R, et al.
Micromachines (Basel)
. 2018 Nov;
9(3).
PMID: 30424062
The use of blood samples as liquid biopsy is a label-free method for cancer diagnosis that offers benefits over traditional invasive biopsy techniques. Cell sorting by acoustic waves offers a...
3.
Virumbrales-Munoz M, Ayuso J, Olave M, Monge R, de Miguel D, Martinez-Lostao L, et al.
Sci Rep
. 2017 Sep;
7(1):11998.
PMID: 28931839
The tumour microenvironment is very complex, and essential in tumour development and drug resistance. The endothelium is critical in the tumour microenvironment: it provides nutrients and oxygen to the tumour...
4.
Ayuso J, Monge R, Martinez-Gonzalez A, Virumbrales-Munoz M, Llamazares G, Berganzo J, et al.
Neuro Oncol
. 2017 Jan;
19(4):503-513.
PMID: 28062831
Background: Glioblastoma (GBM) is one of the most lethal tumor types. Hypercellular regions, named pseudopalisades, are characteristic in these tumors and have been hypothesized to be waves of migrating glioblastoma...
5.
Ayuso J, Virumbrales-Munoz M, Lacueva A, Lanuza P, Checa-Chavarria E, Botella P, et al.
Sci Rep
. 2016 Nov;
6:36086.
PMID: 27796335
The physical microenvironment of tumours is characterized by heterotypic cell interactions and physiological gradients of nutrients, waste products and oxygen. This tumour microenvironment has a major impact on the biology...
6.
Marti Nez-Gonzalez A, Calvo G, Ayuso J, Ochoa I, Fernandez L, Perez-Garcia V
Adv Exp Med Biol
. 2016 Oct;
936:11-29.
PMID: 27739041
This chapter explores the use of mathematical models as promising and powerful tools to understand the complexity of tumors and their, frequently, hypoxic environment. We focus on gliomas, which are...
7.
de Miguel D, Gallego-Lleyda A, Ayuso J, Pejenaute-Ochoa D, Jarauta V, Marzo I, et al.
Cancer Lett
. 2016 Oct;
383(2):250-260.
PMID: 27725224
During the last years, a great effort has been invested into developing new TRAIL formulations with increased bioactivity, trying to overcome the resistance to conventional soluble TRAIL (sTRAIL) exhibited by...
8.
Martinez-Herrero S, Larrayoz I, Ochoa-Callejero L, Fernandez L, Allueva A, Ochoa I, et al.
Front Physiol
. 2016 Jul;
7:280.
PMID: 27445864
Despite recent advances in the understanding and treatment options for osteoporosis, this condition remains a serious public health issue. Adrenomedullin (AM) is a regulatory peptide with reported activity on bone...
9.
Stojkovic S, Podolski-Renic A, Dinic J, Pavkovic Z, Ayuso J, Fernandez L, et al.
Molecules
. 2016 Jun;
21(7).
PMID: 27355941
Chemoresistance and invasion properties are severe limitations to efficient glioma therapy. Therefore, development of glioma in vivo models that more accurately resemble the situation observed in patients emerges. Previously, we...
10.
de Miguel D, Gallego-Lleyda A, Ayuso J, Pawlak A, Conde B, Ochoa I, et al.
Recent Pat Anticancer Drug Discov
. 2016 Mar;
11(2):197-214.
PMID: 26924736
Background: Apo2-ligand/TRAIL, a member of the TNF cytokine superfamily capable of inducing apoptosis on tumor cells while sparing normal cells, is a promising anti-tumor agent. However, about 50% of human...